Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium butyricum CBM588 vs Rifaximin in SUDD
NCT06852274Completed
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Open-label trial (2 arms). Primary endpoint: Change in Symptoms of Diverticular Disease at 12 months. Started Mar 2023; status: completed.
Beyond the preview
Go deeper on NCT06852274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852274.